LMR (Lymphocyte–Monocyte Ratio): Understanding Your Blood Test Series

1. Overview: What this test reveals and why it is important

The lymphocyte–monocyte ratio (LMR) is a simple, inexpensive inflammatory marker derived from the complete blood count with differential. It is calculated by dividing the absolute lymphocyte count by the absolute monocyte count.

LMR reflects the balance between two key white blood cell lineages:

· Lymphocytes are the orchestrators of adaptive immunity – they include T cells, B cells, and natural killer cells. They defend against viral infections, surveil for malignancy, and regulate immune responses.

· Monocytes are innate immune cells that differentiate into macrophages and dendritic cells. They phagocytose pathogens, present antigens, and drive chronic inflammation.

A low LMR indicates either lymphopenia (reduced lymphocytes), monocytosis (elevated monocytes), or both. This pattern signals immune dysregulation, systemic inflammation, and an unfavourable balance between adaptive and innate immunity. A high LMR generally reflects robust adaptive immunity and low inflammatory activity.

Clinical utility: LMR is not a diagnostic test but a prognostic marker. It has been extensively studied in:

· Oncology – low LMR independently predicts poorer survival in solid tumours (colorectal, lung, breast, gastric, hepatocellular) and haematological malignancies (lymphoma, leukaemia).

· Cardiovascular disease – low LMR associates with adverse outcomes after myocardial infarction, stroke, and peripheral artery disease.

· Infectious diseases – low LMR correlates with severity in sepsis, tuberculosis, and HIV.

· Autoimmune disorders – low LMR reflects disease activity in rheumatoid arthritis, lupus, and inflammatory bowel disease.

LMR is cheap, universally available, and can be trended over time. It must always be interpreted alongside the clinical context, absolute cell counts, and other inflammatory markers (CRP, ESR).

---

2. What does it measure

a. Units of measurement

· Dimensionless ratio – calculated as:

· LMR = Absolute lymphocyte count (×10⁹/L or /μL) ÷ Absolute monocyte count (×10⁹/L or /μL)

· Since both numerator and denominator share the same unit, the ratio is unit‑free.

b. Normal Range and Optimal Targets

(Reference intervals vary by age, sex, ethnicity, and laboratory; the following are derived from large population studies and prognostic cut‑points.)

Adults:

· Optimal / low risk: LMR greater than 3.0

· Normal / acceptable: LMR 2.5–3.0

· Borderline low: LMR 2.0–2.5

· Low / adverse prognosis: LMR less than 2.0

· Severely low / high risk: LMR less than 1.5

Children:

· Normal ranges are age‑dependent; physiologically higher lymphocyte counts in infancy and childhood produce higher LMR.

· Infants and toddlers: often 3.0–8.0

· Older children: 2.5–5.0

· Use age‑matched reference ranges from the reporting laboratory.

Interpretation notes:

· LMR is a continuous variable; there is no universal threshold. Different diseases use different cut‑points (e.g., cancer studies often use LMR <2.5–3.0 as a prognostic cut‑off).

· Isolated low LMR with normal absolute counts should prompt repeat testing; transient viral illness or stress can cause temporary lymphopenia.

· Very high LMR (e.g., >8.0) is uncommon in adults and may indicate lymphocytosis (infection, leukaemia) or monocytopenia (rare); investigate if persistent.

· Always examine the absolute lymphocyte and monocyte counts – the ratio alone does not reveal which lineage is deranged.

---

3. Other factors connected to this

a. Direct correlation (factors that directly lower LMR)

LMR is decreased by lymphopenia, monocytosis, or both.

Factors that cause lymphopenia (↓ lymphocytes, ↓ LMR):

· Acute stress / critical illness: trauma, surgery, myocardial infarction – cortisol‑mediated.

· Infections: viral (HIV, influenza, COVID‑19, hepatitis), bacterial sepsis, tuberculosis.

· Immunosuppressive therapy: corticosteroids, chemotherapy, radiation, calcineurin inhibitors, mycophenolate.

· Autoimmune diseases: SLE, rheumatoid arthritis, sarcoidosis.

· Malnutrition / protein‑energy wasting: alcoholism, anorexia nervosa.

· Genetic: DiGeorge syndrome, severe combined immunodeficiency (SCID).

· Haematological: aplastic anaemia, advanced lymphoma, leukaemia.

· Ageing: physiological decline in T‑cell production.

Factors that cause monocytosis (↑ monocytes, ↓ LMR):

· Chronic inflammation / autoimmune disease: rheumatoid arthritis, SLE, inflammatory bowel disease, sarcoidosis.

· Chronic infections: tuberculosis, fungal infections, brucellosis, syphilis, protozoal (leishmaniasis, malaria).

· Malignancy: Hodgkin lymphoma, non‑Hodgkin lymphoma, acute myeloid leukaemia (monocytic subtypes), chronic myelomonocytic leukaemia (CMML).

· Haematological disorders: myeloproliferative neoplasms, haemolytic anaemia, immune thrombocytopenia.

· Post‑splenectomy: monocytes increase (normally cleared by spleen).

· Recovery phase of bone marrow suppression: rebound monocytosis after chemotherapy.

· Medications: granulocyte colony‑stimulating factor (G‑CSF), some antipsychotics.

Thus, low LMR is associated with:

· Acute and chronic inflammation.

· Immunosuppression (therapeutic or disease‑induced).

· Haematological malignancy.

· Poor nutritional status.

· Advanced age and frailty.

b. Indirect correlation (factors that influence LMR interpretation or cause artefactual changes)

· Circadian rhythm: lymphocyte counts are lowest in the morning, highest at night; monocyte counts also fluctuate. For serial comparisons, collect blood at a consistent time (usually morning).

· Exercise: intense acute exercise causes transient lymphocytosis followed by lymphopenia; defer testing after strenuous exertion.

· Pregnancy: mild lymphopenia in third trimester; monocyte count may rise; LMR often decreases physiologically. Not a reliable marker during pregnancy.

· Smoking: chronic smokers often have elevated leukocytes, including monocytes, which may lower LMR.

· Alcohol: chronic alcoholism causes lymphopenia and monocytosis; LMR decreases.

· Medications:

· Decrease LMR: corticosteroids, chemotherapy, immunosuppressants.

· Increase LMR: G‑CSF may increase monocytes (decrease LMR) or lymphocytes (variable); not predictable.

· Splenectomy: monocytosis without lymphopenia → LMR decreases.

· Assay variability: automated haematology analysers may misclassify blasts or atypical cells, affecting differential counts. Manual review if abnormal.

---

4. Disorders related to abnormal values

a. When LMR is low (clinically significant – adverse prognostic marker)

Oncology:

· Solid tumours: colorectal, lung, breast, gastric, hepatocellular, pancreatic – pre‑treatment low LMR predicts shorter overall and disease‑free survival.

· Haematological malignancies:

· Hodgkin lymphoma: low LMR independently predicts poorer response and survival.

· Non‑Hodgkin lymphoma, chronic lymphocytic leukaemia: low LMR correlates with aggressive disease.

· Acute myeloid leukaemia: low LMR at diagnosis associated with lower remission rates.

Cardiovascular disease:

· Acute coronary syndrome / myocardial infarction: low LMR on admission predicts higher in‑hospital and long‑term mortality.

· Heart failure: low LMR correlates with disease severity and poor outcomes.

· Ischaemic stroke: low LMR independently predicts worse functional outcome and mortality.

Infectious diseases:

· Sepsis / bacteraemia: low LMR at presentation predicts progression to septic shock and death.

· Tuberculosis: low LMR correlates with extensive disease and delayed treatment response.

· HIV: low LMR (due to lymphopenia) reflects disease progression and immunodeficiency.

Autoimmune / inflammatory diseases:

· Rheumatoid arthritis, SLE, inflammatory bowel disease: low LMR reflects active disease; normalises with successful immunosuppression.

· Sarcoidosis: low LMR associated with progressive pulmonary disease.

Other:

· Chronic kidney disease: low LMR predicts cardiovascular events and mortality.

· Malnutrition / frailty: low LMR is a marker of immunosenescence.

b. When LMR is high (usually favourable, but context‑dependent)

· Generally desirable: high LMR indicates robust lymphocyte counts and low monocyte‑driven inflammation.

· Physiological: children, healthy adults with regular exercise.

· Lymphocytosis: infections (EBV, pertussis), chronic lymphocytic leukaemia – LMR may be very high, but this is not protective if due to malignancy.

· Monocytopenia: rare; may occur after chemotherapy, in aplastic anaemia, or with certain medications.

· Recovery phase: after bone marrow transplant or chemotherapy, lymphocyte recovery may precede monocyte recovery, transiently raising LMR.

Interpretation note: An isolated high LMR in an otherwise healthy, asymptomatic individual is not a cause for concern and does not require investigation.

---

5. Best way to address aberrant levels

Important principle: LMR is a marker, not a disease. There is no treatment to directly raise LMR. Intervention must target the underlying condition causing lymphopenia or monocytosis. Normalising LMR is a sign that the underlying disease is controlled, inflammation is subsiding, or nutritional status is improving.

a. Quick ways or using Medications

There is no medication approved to increase LMR. The following interventions address the underlying causes:

For lymphopenia:

· Treat the underlying cause:

· Infections: appropriate antimicrobial or antiviral therapy.

· Immunosuppressive drugs: reduce dose if possible, or switch to less lymphotoxic agent.

· Corticosteroid‑induced lymphopenia: taper steroids when clinically feasible.

· HIV: antiretroviral therapy restores CD4 counts.

· Nutritional deficiencies: replace vitamin B12, folate, zinc, protein.

· Granulocyte colony‑stimulating factor (G‑CSF) / granulocyte‑macrophage CSF (GM‑CSF): used to shorten neutropenia, not for lymphopenia; may increase monocytes (lower LMR).

· Interleukin‑2 (IL‑2): experimental for lymphocyte recovery; not routine.

For monocytosis:

· Treat the underlying inflammatory or malignant condition:

· Autoimmune disease: disease‑modifying antirheumatic drugs (DMARDs), biologics, corticosteroids.

· Chronic infection: appropriate antimicrobial therapy.

· Myeloproliferative neoplasms / CMML: cytoreductive therapy (hydroxyurea), targeted therapy (e.g., ruxolitinib), or clinical trial.

· Splenectomy‑induced monocytosis: no treatment required; benign.

Do not self‑prescribe – all prescription medications require medical supervision.

b. Using Supplements or Holistic medicine

Supplements with evidence for supporting lymphocyte function and reducing inflammation – as adjuncts to definitive therapy:

· Vitamin D:

· Deficiency is associated with lymphopenia and impaired immune function.

· Supplementation improves lymphocyte proliferation and reduces inflammatory monocyte activation.

· Preferred: D3 (cholecalciferol) from lichen.

· Dose: 600–2000 IU/day for maintenance; higher doses for deficiency correction (under guidance).

· Zinc:

· Essential for T‑cell development and function; deficiency causes lymphopenia.

· Supplementation in deficient individuals increases lymphocyte counts and improves LMR.

· Preferred form: zinc picolinate or zinc citrate.

· Dose: 15–30 mg elemental zinc/day; monitor copper with long‑term use.

· Vitamin B12 and folate:

· Deficiency causes ineffective haematopoiesis, including lymphopenia.

· Use methylcobalamin and methylfolate – active forms, avoid synthetic folic acid and cyanocobalamin.

· Dose: methylcobalamin 1000–2000 mcg/day, methylfolate 400–1000 mcg/day if deficient.

· Omega‑3 fatty acids (EPA/DHA):

· Reduce systemic inflammation, may lower monocyte counts and modestly improve lymphocyte function.

· Preferred source: Algae oil – sustainable, plant‑based, direct EPA/DHA, no marine contaminants.

· Avoid conventional fish oil (overfishing, ocean pollution, ethical concerns).

· Dose: 2–4 g/day EPA/DHA for anti‑inflammatory effect.

· Vitamin C:

· Supports immune cell function; may reduce oxidative stress.

· High‑dose intravenous vitamin C is used experimentally in sepsis, but oral supplementation for LMR improvement lacks robust evidence.

· Selenium:

· Co‑factor for antioxidant enzymes; deficiency impairs lymphocyte proliferation.

· Supplementation in deficient individuals may improve immune function.

· Probiotics / prebiotics:

· Modulate gut microbiota; emerging evidence suggests they may reduce systemic inflammation and support adaptive immunity.

· Preferred sources: fermented plant foods (kimchi, sauerkraut, kombucha); standardised probiotic supplements with documented strains.

· Curcumin (turmeric):

· Anti‑inflammatory; may reduce monocyte activation.

· Use phytosomal, liposomal, or with piperine for bioavailability.

· Avoid products with added synthetic folic acid or cyanocobalamin.

· Green tea catechins (EGCG):

· Anti‑inflammatory, immunomodulatory.

· Use beverage (2–3 cups/day) rather than concentrated extracts (hepatotoxicity risk).

· Ashwagandha (Withania somnifera):

· Adaptogen; may reduce stress‑induced lymphopenia.

· Limited evidence; use standardised extracts from GMP‑certified manufacturers.

· Reishi mushroom (Ganoderma lucidum):

· Beta‑glucans; immunomodulatory, may enhance lymphocyte activity.

· Preferred source: fruiting body extract, certified organic.

· Always consult a qualified practitioner; herbs and supplements can interact with medications.

Supplements to avoid:

· Products with added synthetic folic acid or cyanocobalamin – use methylfolate and methylcobalamin if needed.

· Unregulated herbal blends with undisclosed ingredients.

· High‑dose vitamin E – may impair immune function.

c. Using Diet and Foods (following a plant‑forward, ecologically sustainable approach)

Diet is a cornerstone of immune health and inflammation control. A well‑designed, nutrient‑dense plant‑based diet supports lymphocyte function, modulates monocyte activity, and promotes a favourable LMR.

Core dietary principles – what to emphasise:

· Anti‑inflammatory dietary pattern:

· Mediterranean‑style plant‑forward diet – abundant vegetables, fruits, legumes, whole grains, nuts, seeds, olive oil.

· High in polyphenols, fibre, unsaturated fats, and antioxidants.

· Low in refined carbohydrates, added sugars, and saturated fats.

· Adequate protein intake:

· Essential for lymphocyte synthesis and immune competence.

· Plant‑based protein sources (hierarchy adhered):

· Primary: legumes (lentils, chickpeas, beans, soy products – tofu, tempeh, edamame).

· Fungi / algae: mycoprotein (Quorn), spirulina, chlorella.

· Biotechnology: precision‑fermented dairy proteins (animal‑free whey, casein) – acceptable emerging options.

· Dairy / eggs: permitted but not emphasised; low‑fat fermented dairy (yoghurt, kefir) if tolerated.

· Meat, poultry, fish: deliberately omitted. Effective plant‑based alternatives exist to meet all protein requirements for immune health.

· Zinc‑rich plant foods:

· Pumpkin seeds, hemp seeds, chickpeas, lentils, cashews, quinoa.

· Soaking and sprouting legumes and seeds reduces phytate and enhances zinc absorption.

· Vitamin B12:

· No reliable plant‑based whole food source. Must be supplemented or obtained from fortified foods (plant milks, nutritional yeast with methylcobalamin).

· Precision‑fermented B12 – ecologically responsible, non‑animal, preferred.

· Folate:

· Abundant in leafy greens, legumes, asparagus, beets, sunflower seeds.

· Deficiency impairs lymphocyte proliferation.

· Vitamin C‑rich foods:

· Citrus fruits, guava, bell peppers, broccoli, kiwi, strawberries, amla (Indian gooseberry).

· Vitamin D:

· Sunlight exposure primary; fortified plant milks; supplement from lichen if needed.

· Iron:

· Iron deficiency impairs lymphocyte function.

· Plant sources: lentils, chickpeas, tofu, pumpkin seeds, quinoa, fortified cereals.

· Enhance absorption with vitamin C; avoid tea/coffee with meals.

· Selenium:

· Brazil nuts (1–2 per day), sunflower seeds, mushrooms, whole grains.

· Omega‑3 fatty acids:

· ALA sources: ground flaxseeds, chia seeds, hemp seeds, walnuts.

· Direct EPA/DHA: microalgae (spirulina, chlorella – limited amounts); algae oil supplements for therapeutic doses.

· Polyphenol‑rich foods:

· Berries, green tea, dark chocolate (≥70% cocoa), extra virgin olive oil, turmeric, ginger, cruciferous vegetables.

· Fermented plant foods:

· Kimchi, sauerkraut, kombucha, miso, tempeh – support gut microbiome diversity and may reduce systemic inflammation.

· Mushrooms:

· Shiitake, maitake, oyster, reishi – beta‑glucans and ergothioneine; immunomodulatory.

What to avoid or severely limit:

· Ultra‑processed foods, refined carbohydrates, added sugars – promote inflammation and impair immune function.

· Excess alcohol – causes lymphopenia and monocytosis; abstinence recommended if LMR is low.

· Trans fats – partially hydrogenated oils.

· Saturated fats – excess intake may promote inflammation.

· Smoking – single most important modifiable risk factor for low LMR; cessation improves lymphocyte counts and reduces monocytes.

Lifestyle factors with proven benefit for LMR:

· Regular moderate aerobic exercise: 30–60 minutes, most days – enhances lymphocyte circulation, reduces chronic inflammation.

· Stress reduction: chronic stress elevates cortisol, causing lymphopenia; mindfulness, meditation, adequate sleep.

· Smoking cessation: as above.

· Weight loss: in overweight/obese individuals, weight loss reduces monocyte counts and inflammatory markers.

---

6. How soon can one expect improvement and the ideal time frame to retest

LMR can change rapidly in response to acute illness or interventions – within days to weeks.

For acute conditions (infection, stress, surgery):

· LMR nadir occurs 24–72 hours after insult; recovery begins within 3–7 days after resolution.

· Repeat testing in 1–2 weeks to confirm normalisation.

For chronic conditions (autoimmune disease, malignancy, nutritional deficiency):

· Immunosuppressive therapy: LMR improves within 4–8 weeks of effective treatment (e.g., corticosteroids, DMARDs, biologics).

· Nutritional repletion (zinc, B12, folate): lymphocyte counts increase within 2–4 weeks; LMR improves over 4–8 weeks.

· Antiretroviral therapy in HIV: CD4 recovery is slow; LMR improves over 3–6 months.

· Weight loss / exercise: LMR improvement detectable in 3–6 months with sustained lifestyle change.

For supplementation:

· Vitamin D, zinc, B12: if deficient, lymphocyte response within 4–8 weeks; monitor LMR at 2–3 months.

Retesting interval summary:

· Acute illness / hospitalisation: repeat in 1–2 weeks after clinical recovery.

· Chronic disease on treatment: every 3–6 months to monitor response.

· Nutritional intervention: repeat at 2–3 months, then annually if stable.

· Routine health screen: every 1–2 years in stable, healthy individuals.

Do not retest LMR more often than every 2 weeks – changes in stable chronic disease are gradual.

---

Conclusion

The lymphocyte–monocyte ratio is a silent sentinel of immune balance. A low LMR does not diagnose a specific disease, but it sounds an alarm: the adaptive immune system is suppressed, the innate inflammatory response is overactive, or both. It is a cry for investigation – and, when persistently low, a call to action.

There is no pill to raise LMR. The path to a favourable ratio is the path to immune health: treat the underlying infection, calm the autoimmune fire, nourish the malnourished, and remove the toxins of tobacco and excess alcohol. A plant‑based, ecologically responsible diet – rich in legumes, whole grains, nuts, seeds, mushrooms, and algae‑derived omega‑3s – provides the nutrients necessary for lymphocyte resilience and the anti‑inflammatory compounds that temper monocyte activity.

We omit meat from these recommendations because it is unnecessary. The immune system does not require animal flesh; it requires adequacy of protein, zinc, iron, and vitamins – all of which can be obtained from plants, fungi, algae, and precision‑fermented sources. The ecological imperative aligns with the immunological one: a diet that sustains the planet also sustains the lymphocytes that defend it.

LMR is a number. The patient is the story. Listen to both – and when the number is low, treat the story, not the statistic.

---x-x-

Note on dietary recommendations on this site:

For the sake of our environment we adhere to the following dietary preference hierarchy:

1. Plant‑based

2. Fungi / algae / fermented

3. Biotechnology / lab‑grown / cultures

4. Dairy / eggs

5. Meat / fish / poultry (only if no effective alternative exists)

This approach reflects ecological responsibility, antibiotic stewardship, and the urgent need to reduce the environmental footprint of dietary recommendations.

-x-x-